1 Koster MJ, Warrington KJ. Classification of large vessel vasculitis: Can we separate giant cell arteritits from Takaysu arteritis? Presse Med. 2017;46(7–8 Pt 2):e205–e213.
2 Petitpierre S, Bart PA, Leimgruber A, Prior J, Spertini F. Les artérites des grands vaisseaux: maladie de Horton et maladie de Takayasu. Rev Med Suisse. 2007;32254.
3 Spertini F. De l’espoir pour les pathologies inflammatoires chroniques: l’antirécepteur de l’IL-6 tocilizumab. Rev Med Suisse. 2017;20–2.
4 Seyahi E. Takayasu arteritis, an update. Curr Opin Rheumatol. 2017;29(1):51–6.
5 Sadrkhah A, Seebach JD, Muller Y. Artérite des grands vaisseaux: pathogenèse, diagnostic et prise en charge. Rev Med Suisse. 2017;758–62.
6 Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, et al. Pentraxin-3, a marker of disease activity in Takayasu arteritis. Ann Intern Med. 2011;155(7):425–3.
7 Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore). 2015;94(14):e622.
8 Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34.